Advertisement

Topics

Latest Diabetic Nephropathy - Kidney Disease NewsRSS

13:00 EST 19th November 2017 | BioPortfolio

The new battleground of prime time media, disease, and death

I first noticed this phenomenon while watching the world news on a weekday after work.  It was a commercial for a new diabetes medicine that showed overweight people dancing at a barbecue, cooking and enjoying life.  How different this was from my day in the wound clinic, where I saw patient after patient with obesity, […]

Diabetic Nephropathy Market Insights, Epidemiology and Market Forecast 2025 [Report Updated: 10102017] Prices from USD $4600

DelveInsight's Diabetic Nephropathy Market Insights, Epidemiology and Market Forecast Market Insights, Epidemiology and Market Forecast 2025 report provides an overview of the disease and in depth research related to Diabetic Nephropathy Market Insights, Epidemiology and Market Forecast for the 7MM United States, Germany, France, Italy, Spain and UK for the study period undertaken from 2015202...

Dry eye disease Market Insights, Epidemiology and Market Forecast 2025 [Report Updated: 10102017] Prices from USD $4600

DelveInsight's Dry eye disease Market Insights, Epidemiology and Market Forecast Market Insights, Epidemiology and Market Forecast 2025 report provides an overview of the disease and in depth research related to Dry eye disease Market Insights, Epidemiology and Market Forecast for the 7MM United States, Germany, France, Italy, Spain and UK for the study period undertaken from 20152025.This rep...

AMPK activator reduces glucose level in type 2 diabetes in phase 2a trial

A novel AMP-activated protein kinase activator showed glucose reduction and decreased cardiovascular risk factors in people with type 2 diabetes in a phase 2a trial, according to a press release from the drug’s developer.The first-in-class drug (O304, Betagenon/Baltic Bio) activates AMP-activated protein kinase (AMPK), which regulates energy balance. By activating this protein, the researchers a...

Alzheimer's disease AD Market Insights, Epidemiology and Market Forecast 2025 [Report Updated: 10102017] Prices from USD $4600

DelveInsight's Alzheimer's disease AD Market Insights, Epidemiology and Market Forecast Market Insights, Epidemiology and Market Forecast 2025 report provides an overview of the disease and in depth research related to Alzheimer's disease AD Market Insights, Epidemiology and Market Forecast for the 7MM United States, Germany, France, Italy, Spain and UK for the study period undertaken from 201...

Global Gaucher Disease Market Data Survey Report 2025 [Report Updated: 01011970] Prices from USD $1500

SummaryGaucher disease is an inherited disorder that affects many of the body's organs and tissues. The signs and symptoms of this condition vary widely among affected individuals.The global Gaucher Disease market will reach Volume Million USD in 2017 with CAGR xx% 20182025. The main contents of the report including:Global market size and forecastRegional market size, production data and export i...

Gaucher's disease Market Insights, Epidemiology and Market Forecast 2025 [Report Updated: 10102017] Prices from USD $4600

DelveInsight's Gaucher's disease Market Insights, Epidemiology and Market Forecast Market Insights, Epidemiology and Market Forecast 2025 report provides an overview of the disease and in depth research related to Gaucher's disease Market Insights, Epidemiology and Market Forecast for the 7MM United States, Germany, France, Italy, Spain and UK for the study period undertaken from 20152025.This...

Evoke Pharma Inc EVOK Financial and Strategic SWOT Analysis Review [Report Updated: 13112017] Prices from USD $300

SummaryEvoke Pharma Inc Evoke Pharma is a specialty pharmaceutical company that develops drugs to treat gastrointestinal diseases. The company's lead product candidate EVK001 is under clinical development that provides relief from the symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus. Its Gimoti, is in late stage clinical testing for the treatment ...

Somatostatin Receptor Type 2 SRIF1 or SSTR2 Pipeline Review, H2 2017 [Report Updated: 31102017] Prices from USD $3500

Somatostatin Receptor Type 2 SRIF1 or SSTR2 Pipeline Review, H2 2017SummarySomatostatin Receptor Type 2 SRIF1 or SSTR2 pipeline Target constitutes close to 11 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes. The latest report Somatostatin Receptor Type 2 SRIF1 or SSTR2 Pipeline Review, H2 2017, outlays comprehensive infor...

MKSAP: 45-year-old man with type 2 diabetes mellitus

Test your medicine knowledge with the MKSAP challenge, in partnership with the American College of Physicians. A 45-year-old man is evaluated during an annual routine health maintenance visit. History is notable for type 2 diabetes mellitus (diet controlled) diagnosed 3 months ago. Family history is significant for his father who developed end-stage kidney disease due to diabetes […]

Gaucher's disease Epidemiology Forecast to 2025 [Report Updated: 10102017] Prices from USD $2200

DelveInsight Gaucher's disease Epidemiology Forecast To 2025 provides an overview of the epidemiology trends of Gaucher's disease in seven major markets US, France, Germany, Italy, Spain, UK and Japan. It includes 10 years epidemiology historical and forecasted data of Gaucher's disease prevalent or incident cases segmented by age, sex and subpopulations. The Report also discusses the prevailing ...

Astrocytes linked to Alzheimer’s disease for the first time.

Alzheimer’s disease (AD) is the most common dementia type, with no treatment to slow down the progression of the disease currently available. The mechanisms of AD are poorly understood with drug therapy focused on restoring the normal function of neurons and microglia. Now, a study from researchers at University of Eastern Finland shows that astrocytes promote the decline of neuron

GI Dynamics to Provide Corporate Update and 2017 Third Quarter Results

GI Dynamics® Inc. (ASX: GID), a medical device company that has commercialized EndoBarrier® in Europe, the Middle East and South America for patients with type 2 diabetes and obesity, announces it will provide a corporate update and discuss 2017 third quarter results to investors. The company will host a webcast at 4 PM EST 21 November 2017 | 8 ...

30% of heart patients still taking prescribed statins 3 years later

While 71 percent of heart patients are prescribed statins after hospital

Gastroesophageal Reflux Disease GERDEpidemiology Forecast to 2025 [Report Updated: 10102017] Prices from USD $2200

DelveInsight Gastroesophageal Reflux Disease GERD Epidemiology Forecast To 2025 provides an overview of the epidemiology trends of Gastroesophageal Reflux Disease GERD in seven major markets US, France, Germany, Italy, Spain, UK and Japan. It includes 10 years epidemiology historical and forecasted data of Gastroesophageal Reflux Disease GERD prevalent or incident cases segmented by age, sex and ...

Nearly 1 in 7 patients with diabetes have poor glycemic control

About one in seven patients with diabetes had poor glycemic control between 2007 and 2014 despite an increase in the frequency of self-reported testing and patient awareness of hemoglobin A1c, according to data published in JAMA.“In 2014, an estimated 30.3 million people (9.4%) in the United States had diabetes. Improving glycemic control reduces the risk of diabetes-related vascular complicatio...

ETDRS, ultra-widefield imaging on par for identifying retinopathy severity

Lloyd P. AielloNEW ORLEANS — In a baseline data review, ETDRS and ultra-widefield imaging appear comparable for determining diabetic retinopathy severity within the ETDRS fields, according to results of the ongoing Diabetic Retinopathy Clinical Research Network Protocol AA trial presented here.“There is moderate to substantial agreement between ETDRS photos and ultra-widefield images masked to...

Pfizer's Drug Approved As Adjuvant Treatment In Recurrent Renal Cell Carcinoma

NewsPfizer receives FDA approval expanding the use of Sutent to include the adjuvant treatment of adult patients at high risk of recurrent renal cell carcinoma following surgical removal of the cancerous kidney.

Chronic Obstructive Pulmonary Disease COPD Epidemiology Forecast to 2025 [Report Updated: 10112017] Prices from USD $2200

DelveInsight Chronic Obstructive Pulmonary Disease COPD Epidemiology Forecast To 2025 provides an overview of the epidemiology trends of Chronic Obstructive Pulmonary Disease COPD in seven major markets US, France, Germany, Italy, Spain, UK and Japan. It includes 10 years epidemiology historical and forecasted data of Chronic Obstructive Pulmonary Disease COPD prevalent or incident cases segmente...

Are You Keeping An Eye On EARS And 6 Other Pharma Stocks?

If the timeline is adhered to, this clinical-stage company, focused on developing drugs for disorders concerned especially with the ear, nose, and throat, has an important catalyst coming up this quarter.

Proprotein Convertase Subtilisin/Kexin Type 9 Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21. Pipeline Review, H2 2017 [Report Updated: 10102017] Prices from USD $3500

Proprotein Convertase Subtilisin/Kexin Type 9 Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21. Pipeline Review, H2 2017SummaryProprotein Convertase Subtilisin/Kexin Type 9 Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21. pipeline Target cons...

NIH Grant Awarded to Weill Cornell Medicine for Fibrosis Research

Weill Cornell Medicine researchers have received a grant from the National Heart, Lung, and Blood Institute of the National Institutes of Health to conduct an in-depth study of the mechanisms that cause scar tissue to form in the lung and kidney.

Loss of efficacy after switching to biosimilar infliximab in Behcet’s patients

Authors from the Division of Rheumatology at the Hospital of Prato, Italy report on three patients with Behçet’s disease that experienced disease relapses after switching from the originator infliximab, Remicade, to biosimilar infliximab [1].

Prescribe exercise like you prescribe medicine

We have all seen and heard the story: a patient who is overweight and has heart problems (or arthritis, diabetes, low back pain or any number of other chronic conditions) is told by their doctor that they need to exercise. The patient agrees, “Yes, I really will try to start an exercise program.” Six months […]

Tolvaptan reduces eGFR decline in patients with polycystic kidney disease

1. Estimated glomerular filtration rate (eGFR) declined less over one year of treatment for patients with later-stage autosomal dominant polycystic kidney disease (ADPKD) taking tolvaptan than those taking placebo. 2. Liver enzyme increases above 3 times the upper limit of normal (ULN) and serious liver-related events occurred more in the tolvaptan group than the placebo […]

Quick Search
Advertisement
 

review and buy Diabetic Nephropathy - Kidney Disease market research data and corporate reports here